IgNS Home

MMN Product Characteristics Brochure

Review considerations for administering GAMMAGARD LIQUID, with key details on its formulation and patient risk factors.

Takeda

This site is intended for US residents and governed by US laws and government regulations. Please see our online Privacy Policy for more information. ©2022 Takeda Pharmaceuticals U.S.A., Lexington, MA 02421. 1-877-TAKEDA-7. All rights reserved. OnePath is a trademark or registered trademark of Shire, a Takeda company. CUVITRU, HYQVIA, Gammagard and MYIGSOURCE are trademarks or registered trademarks of Baxalta Incorporated, a Takeda company. Takeda and the Takeda logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited.

US-XMP-0650v6.0   08/21

For US Healthcare Professionals Only

The information on this website has been specifically created for US healthcare professionals (HCPs).

Agree and continue to site

You are now leaving the Homepage and entering the Medical Affairs Area.

Yes, I want to leave